Index RUT
P/E -
EPS (ttm) -9.16
Insider Own 12.91%
Shs Outstand 94.54M
Perf Week 1.03%
Market Cap 4.92B
Forward P/E -
EPS next Y -6.33
Insider Trans 4.88%
Shs Float 82.34M
Perf Month 15.45%
Income -746.61M
PEG -
EPS next Q -1.70
Inst Own 88.28%
Short Float 10.90%
Perf Quarter 29.22%
Sales 0.00M
P/S -
EPS this Y -52.93%
Inst Trans 13.71%
Short Ratio 9.02
Perf Half Y 34.30%
Book/sh 4.16
P/B 12.51
EPS next Y 27.72%
ROA -137.07%
Short Interest 8.98M
Perf Year 93.67%
Cash/sh 4.62
P/C 11.25
EPS next 5Y -
ROE -193.67%
52W Range 25.97 - 62.21
Perf YTD 21.50%
Dividend Est. -
P/FCF -
EPS past 5Y -
ROI -182.13%
52W High -16.41%
Beta 4.12
Dividend TTM -
Quick Ratio 3.27
Sales past 5Y 0.00%
Gross Margin -
52W Low 100.23%
ATR (14) 2.41
Dividend Ex-Date -
Current Ratio 3.27
EPS Y/Y TTM -44.95%
Oper. Margin 0.00%
RSI (14) 59.20
Volatility 4.41% 5.15%
Employees 239
Debt/Eq 0.08
Sales Y/Y TTM -
Profit Margin -
Recom 1.13
Target Price 64.31
Option/Short Yes / Yes
LT Debt/Eq 0.07
EPS Q/Q -175.22%
Payout -
Rel Volume 0.47
Prev Close 52.65
Sales Surprise -
EPS Surprise -104.41%
Sales Q/Q -
Earnings Aug 08 AMC
Avg Volume 995.45K
Price 52.00
SMA20 1.83%
SMA50 17.42%
SMA200 20.14%
Trades
Volume 207,782
Change -1.23%
Date
Action
Analyst
Rating Change
Price Target Change
Sep-16-24 Initiated
Jefferies
Buy
$57
Sep-04-24 Initiated
Bernstein
Outperform
$55
Jul-24-24 Initiated
Morgan Stanley
Overweight
$58
Feb-16-24 Initiated
RBC Capital Mkts
Outperform
$62
Feb-06-24 Initiated
UBS
Buy
$59
Dec-22-23 Initiated
H.C. Wainwright
Buy
$50
Dec-08-23 Initiated
Robert W. Baird
Outperform
$58
Jan-24-23 Initiated
SVB Securities
Outperform
$24
Jan-04-23 Initiated
JP Morgan
Overweight
$23
Dec-02-22 Initiated
BTIG Research
Buy
$24
Oct-26-22 Upgrade
Cantor Fitzgerald
Neutral → Overweight
$158 → $27
Oct-12-22 Initiated
Piper Sandler
Overweight
$23
Aug-19-22 Downgrade
Piper Sandler
Overweight → Neutral
$149
Aug-08-22 Downgrade
Wedbush
Outperform → Neutral
$148.50
May-11-22 Downgrade
SVB Leerink
Outperform → Mkt Perform
$150
Oct-19-21 Resumed
Morgan Stanley
Equal-Weight
$107 → $145
Aug-10-21 Downgrade
UBS
Buy → Neutral
$108 → $109
Aug-03-21 Reiterated
Canaccord Genuity
Buy
$101 → $150
Mar-11-21 Initiated
UBS
Buy
$108
Dec-15-20 Initiated
H.C. Wainwright
Buy
$121
Show Previous Ratings
Oct-07-24 04:13PM
(Investor's Business Daily) +10.75%
09:41AM
(Investor's Business Daily)
Oct-02-24 04:05PM
Oct-01-24 06:00AM
Sep-30-24 04:05PM
07:30AM
Loading…
07:30AM
Sep-23-24 07:30AM
Sep-20-24 07:09PM
Aug-08-24 08:21PM
(Insider Monkey) +5.93%
+6.25%
04:05PM
Jul-01-24 07:00AM
Jun-28-24 10:00AM
May-29-24 07:30AM
07:15AM
May-15-24 11:00AM
09:35AM
Loading…
May-14-24 09:35AM
May-13-24 09:35AM
May-09-24 11:54PM
04:05PM
May-01-24 02:38PM
Apr-26-24 06:00AM
Apr-25-24 11:00AM
Apr-23-24 11:00AM
Apr-22-24 04:05PM
Apr-18-24 06:00AM
Apr-17-24 04:05PM
Apr-13-24 09:00AM
Apr-03-24 10:03PM
Feb-29-24 04:05PM
Jan-25-24 05:31PM
07:00AM
Loading…
Jan-22-24 07:00AM
(The Wall Street Journal) +9.24%
Jan-08-24 07:30AM
Jan-02-24 07:00AM
Dec-31-23 03:01AM
Dec-01-23 04:30PM
Nov-16-23 09:40AM
Nov-14-23 09:15PM
04:05PM
Nov-06-23 08:50AM
Oct-31-23 09:40AM
Oct-19-23 08:50AM
Oct-16-23 07:00AM
Oct-06-23 01:01PM
Oct-05-23 04:05PM
Oct-03-23 08:50AM
Oct-02-23 11:56PM
04:36PM
Sep-29-23 10:00AM
10:00AM
Sep-28-23 07:53AM
Sep-27-23 04:09PM
(Investor's Business Daily) +33.31%
12:25PM
(Investor's Business Daily)
12:00PM
Sep-14-23 07:00AM
Sep-05-23 07:00AM
Aug-09-23 06:01AM
Jul-31-23 09:31AM
06:59AM
Jul-27-23 12:50PM
07:00AM
Jun-27-23 05:31AM
Jun-02-23 09:11AM
Jun-01-23 04:08PM
(Investor's Business Daily) +18.39%
01:01PM
(Investor's Business Daily)
11:29AM
May-31-23 07:00AM
May-25-23 05:00PM
May-24-23 01:30PM
May-12-23 04:30PM
May-05-23 10:43AM
Apr-17-23 07:00AM
Mar-30-23 09:40AM
Mar-25-23 09:22AM
Mar-23-23 04:05PM
11:09AM
Mar-22-23 07:30AM
Mar-14-23 07:30AM
Mar-13-23 11:39AM
Feb-23-23 08:36AM
Feb-21-23 07:30AM
Feb-10-23 02:55PM
Feb-02-23 12:52PM
(Investor's Business Daily)
Jan-06-23 07:58AM
07:30AM
Jan-05-23 09:40AM
Dec-23-22 06:21AM
Nov-29-22 09:35AM
Nov-28-22 09:55AM
Nov-21-22 09:33AM
Nov-09-22 08:35AM
07:00AM
Nov-08-22 11:52AM
Nov-06-22 11:48AM
07:00AM
Nov-01-22 10:01AM
Oct-25-22 08:21PM
04:30PM
Oct-20-22 10:30PM
Oct-18-22 04:12PM
Oct-07-22 03:24AM
Biohaven Ltd. is a global clinical stage biopharmaceutical company, which engages in the discovery, development, and commercialization of therapies for people with neurological and neuropsychiatric diseases. The company was founded on May 2, 2022 and is headquartered in New Haven, CT.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
CHILDS JOHN W Director Oct 02 '24 Buy 47.50 21,052 999,970 21,052 Oct 03 07:01 AM Coric Vlad Chief Executive Officer Oct 02 '24 Buy 47.50 21,052 999,970 861,942 Oct 03 07:00 AM Bailey Gregory Director Sep 24 '24 Buy 44.19 5,000 220,966 1,620,071 Sep 25 07:30 AM CHILDS JOHN W Director Jul 18 '24 Buy 35.67 28,400 1,012,983 2,339,741 Jul 19 08:56 AM Car Bruce Chief Scientific Officer Jun 17 '24 Buy 33.58 30,000 1,007,490 30,000 Jun 20 07:30 AM CHILDS JOHN W Director May 30 '24 Buy 35.58 28,000 996,240 2,311,341 May 31 09:04 AM Bailey Gregory Director May 13 '24 Buy 34.19 15,000 512,877 1,615,071 May 15 07:31 AM CHILDS JOHN W Director May 13 '24 Buy 35.17 28,500 1,002,470 2,283,341 May 14 07:30 AM Bailey Gregory Director Apr 24 '24 Buy 39.18 25,503 999,169 1,600,071 Apr 25 07:32 AM Bailey Gregory Director Apr 22 '24 Buy 41.00 48,780 1,999,980 1,574,568 Apr 23 07:54 AM CHILDS JOHN W Director Apr 22 '24 Buy 41.00 195,121 7,999,961 4,096,512 Apr 23 07:54 AM Coric Vlad Chief Executive Officer Apr 22 '24 Buy 41.00 121,951 4,999,991 1,788,417 Apr 23 07:54 AM Antonijevic Irina Director Dec 29 '23 Option Exercise 0.00 11,000 0 13,535 Dec 29 06:25 PM Antonijevic Irina Director Dec 29 '23 Sale 41.79 11,000 459,662 2,535 Dec 29 06:25 PM
Index -
P/E -
EPS (ttm) -11.08
Insider Own 54.91%
Shs Outstand 8.88M
Perf Week -0.07%
Market Cap 67.09M
Forward P/E -
EPS next Y -
Insider Trans 2.05%
Shs Float 4.00M
Perf Month 0.73%
Income -13.09M
PEG -
EPS next Q -
Inst Own 2.32%
Short Float 0.81%
Perf Quarter -17.43%
Sales 0.18M
P/S 372.71
EPS this Y -
Inst Trans 25.89%
Short Ratio 2.03
Perf Half Y -35.40%
Book/sh -1.86
P/B -
EPS next Y -
ROA -113.90%
Short Interest 0.03M
Perf Year -70.16%
Cash/sh 0.68
P/C 11.07
EPS next 5Y -
ROE -
52W Range 5.85 - 24.62
Perf YTD -44.20%
Dividend Est. -
P/FCF -
EPS past 5Y -12.67%
ROI -
52W High -69.31%
Beta 1.04
Dividend TTM -
Quick Ratio 0.71
Sales past 5Y -39.80%
Gross Margin -1.68%
52W Low 29.15%
ATR (14) 0.61
Dividend Ex-Date -
Current Ratio 0.71
EPS Y/Y TTM -6.88%
Oper. Margin -6761.45%
RSI (14) 53.93
Volatility 7.29% 8.58%
Employees 4
Debt/Eq -
Sales Y/Y TTM 397.22%
Profit Margin -7312.85%
Recom -
Target Price -
Option/Short No / Yes
LT Debt/Eq -
EPS Q/Q 120.72%
Payout -
Rel Volume 0.77
Prev Close 7.65
Sales Surprise -
EPS Surprise -
Sales Q/Q 466.67%
Earnings -
Avg Volume 15.96K
Price 7.55
SMA20 5.96%
SMA50 3.93%
SMA200 -26.94%
Trades
Volume 5,257
Change -1.24%
Oct-02-24 08:30AM
Sep-04-24 06:42PM
Aug-20-24 07:01PM
Aug-09-24 04:15PM
(GlobeNewswire) -5.17%
-10.13%
Jul-29-24 08:30AM
05:00PM
Loading…
Jul-18-24 05:00PM
(GlobeNewswire) -18.15%
+9.84%
May-15-24 07:30AM
May-14-24 04:05PM
Apr-17-24 04:05PM
Mar-26-24 05:04PM
(GlobeNewswire) -11.90%
+33.98%
Serina Therapeutics, Inc. operates as a pharmaceutical company, which engages in the development of polymer technology. Its POZ technology is designed to optimize drug delivery to maximize compliance, therapeutic outcomes, safety, and quality of life for patients. It also offers drugs to treat neurological diseases, cancer, and pain. The company was founded by J. Milton Harris and Michael D. Bentley on March 26, 2024 and is headquartered in Huntsville, AL.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Bailey Gregory Director Sep 20 '24 Buy 6.03 1,137 6,851 63,377 Sep 24 04:30 PM Bailey Gregory Director Sep 19 '24 Buy 6.11 11,679 71,384 62,240 Sep 20 06:59 PM Bailey Gregory Director Sep 18 '24 Buy 6.23 2,709 16,873 50,561 Sep 20 06:59 PM MINTZ STEVEN Director Sep 12 '24 Buy 6.47 6,000 38,814 17,443 Sep 16 06:53 PM Bailey Gregory Director Aug 20 '24 Buy 8.25 1,776 14,652 47,582 Aug 22 05:27 PM Bailey Gregory Director Aug 19 '24 Buy 7.93 6,400 50,760 45,806 Aug 20 04:35 PM Bailey Gregory Director Aug 16 '24 Buy 7.31 6,400 46,780 39,406 Aug 20 04:35 PM Bailey Gregory Director Aug 15 '24 Buy 6.65 6,400 42,577 33,006 Aug 20 04:35 PM MINTZ STEVEN Director Aug 15 '24 Buy 6.59 7,593 50,033 11,443 Aug 19 06:55 PM MINTZ STEVEN Director Aug 15 '24 Buy 6.59 1,350 8,896 12,257 Aug 19 06:55 PM Bailey Gregory Director Aug 14 '24 Buy 7.07 6,400 45,228 26,606 Aug 16 04:20 PM MINTZ STEVEN Director Jun 21 '24 Buy 9.50 5,000 47,500 8,307 Jun 27 08:26 PM MINTZ STEVEN Director Jun 25 '24 Buy 9.00 2,600 23,400 10,907 Jun 27 08:26 PM Bailey Gregory Director May 30 '24 Buy 9.50 5,205 49,448 20,206 May 31 04:18 PM Bailey Gregory Director May 29 '24 Buy 9.50 1,173 11,144 15,001 May 31 04:18 PM Bailey Gregory Director May 28 '24 Buy 9.50 9,019 85,680 13,828 May 29 04:15 PM Bailey Gregory Director May 23 '24 Buy 9.50 2,371 22,524 4,809 May 24 04:15 PM Bailey Gregory Director May 21 '24 Buy 9.50 916 8,702 2,438 May 24 04:15 PM MINTZ STEVEN Director May 21 '24 Buy 9.93 9,151 90,885 9,900 May 23 05:07 PM MINTZ STEVEN Director May 20 '24 Buy 9.43 2,675 25,233 1,240 May 23 05:07 PM MINTZ STEVEN Director May 17 '24 Buy 8.50 554 4,709 554 May 23 05:07 PM Bailey Gregory Director May 21 '24 Buy 9.50 1,422 13,509 1,522 May 23 04:15 PM Bailey Gregory Director May 20 '24 Buy 9.00 100 900 100 May 22 04:15 PM
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite